Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- 
        Clinical Trial InformationTrial Contact: Parker, Melanie; Armatti, Julie M; Frankos, Marie; Torrescano, Tanner; Jones, Jamie; Singh, Sarah H Trial Phone: 321-843-1036 ; 321-843-5284 ; 321-842-8738 ; 321-841-8271 ; 3218412008 ; 321.841.7561 
- 
        IRB No: 24.169.11 Protocol Abbrev: BCC022 Principal Investigator: Jaime C Gonzalez, MD Phase: Drug: Phase II Age Group: Pediatric Secondary Protocol No: BCC022 Treatment: Drug: Tipifarnib; Drug: Naxitamab Therapies Involved: Medication ClinicalTrials.gov ID: NCT06540963 
- 
            ObjectiveTest the safety and tolerability of tipifarnib in combination with naxitimab in patients with cancer 
 To determine the activity of study treatments chosen based on:
 How each subject responds to the study treatment
 How long a subject lives without their disease returning/progressing
- 
            Key EligibilityAge: 
 Subjects must be age ≤ 21 years at initial diagnosis. Subjects must be >12 months of age at enrollment. Safety Run-In (first 6 subjects) must be age 6 years or older.
 Pathology: All subjects must have a pathologically confirmed diagnosis of neuroblastoma at any point in their treatment.
 
            